Pablo Cure, M.D., M.P.H.
Program Director
Clinical and Translational Science Awards Program Branch
Division of Clinical Innovation
Digital & Mobile Technologies Section
Contact Info
Biography
Pablo Cure is a program director in the Digital & Mobile Technologies Section of the Clinical and Translational Science Awards (CTSA) Program within NCATS’ Division of Clinical Innovation, where he manages a portfolio of CTSA Program grants. Prior to joining NCATS in November 2017, Cure was a health scientist administrator at the National Heart, Lung, and Blood Institute (NHLBI), where he oversaw a portfolio of clinical and translational studies, including single and multisite clinical trials, and large observational studies.
Prior to his tenure at NIH, Cure was the LEAP (Laboratory for Entrepreneurial Achievement in Pediatrics) Scholar, focused on innovation, translational science, and entrepreneurship in pediatrics, at Children’s National Health System. He later became the Clinical Research Center scientific director at the Clinical and Translational Science Institute at Children’s National and assistant professor at the George Washington School of Medicine and Health Sciences.
Cure received his M.D. from the Universidad del Norte in Barranquilla, Colombia, and his M.P.H. from the George Washington University. He conducted his postdoctoral fellow research in the Clinical Islet Transplant Program at the University of Miami Leonard M. Miller School of Medicine’s Diabetes Research Institute.
Professional Interests
Cure’s professional interests include digital health, real-world data, and data science to advance clinical and translational science.
Selected Publications
-
Advancing Regulatory Science Through Real-World Data and Real-World Evidence
-
Real-World Data for 21st-Century Medicine: The Clinical and Translational Science Awards Program Perspective
-
Advancing Clinical and Translational Science through Accelerating the Decentralization of Clinical Trials Report 2024
-
Adolescent BMI and Risk of Diabetes Versus Coronary Disease
-
"Creating Hope" and Other Incentives for Drug Development for Children